Previous issue | > Previous issue |

|
|
- Review Article
- An overview of radiation-induced heart disease
- Samer Ellahham
, Amani Khalouf , Mohammed Elkhazendar , Nour Dababo , Yosef Manla
-
Radiat Oncol J. 2022;40(2):89-102. Published online June 21, 2022
-
|
Radiation therapy (RT) has dramatically improved cancer survival, leading to several inevitable complications. Unintentional irradiation of the heart can lead to radiation-induced heart disease (RIHD), including cardiomyopathy, pericarditis, coronary artery disease, valvular heart disease, and conduction system abnormalities. Furthermore, the development of RIHD is aggravated with the addition of chemotherapy. The screening, diagnosis, and follow-up for RIHD in patients who... |
-
-
|
- Original Articles
- Clinical Investigation
- Improving locoregional outcome in high-intermediate-risk and high-risk stage I endometrial cancer with surgical staging followed by brachytherapy
- Candan Demiroz Abakay
, Sonay Arslan , Meral Kurt , Sibel Cetintas
-
Radiat Oncol J. 2022;40(2):103-110. Published online May 25, 2022
-
|
Purpose: This study aims to assess the locoregional efficacy of postoperative vaginal brachytherapy (VBT) alone in patients undergoing surgical staging for early-stage high-intermediate-risk (HIR) and high-risk (HR) endometrial cancer.
Materials and Methods: One hundred and four patients with early-stage HIR and HR endometrial cancer who underwent surgical staging were treated with adjuvant VBT alone. The patients with stage Ib, grade... |
-
-
|
- Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy
- Abhinav V. Reddy
, Colin S. Hill , Shuchi Sehgal , Lei Zheng , Jin He , Daniel A. Laheru , Ana De Jesus-Acosta , Joseph M. Herman , Jeffrey Meyer , Amol K. Narang
-
Radiat Oncol J. 2022;40(2):111-119. Published online May 20, 2022
-
|
Purpose: To investigate the role of pre- and post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with localized pancreatic cancer treated with anti-PD-1 (programmed cell death protein-1) antibody and SBRT.
Materials and Methods: This was a retrospective review of 68 patients with borderline resectable or locally advanced pancreatic cancer treated with anti-PD-1 antibody and SBRT after multi-agent chemotherapy. Immunotherapy... |
-
-
|
- Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction
- Tae Hoon Lee
, Joo Ho Lee , Seong Keun Kwon , Eun-Jae Chung , Hong-Gyun Wu
-
Radiat Oncol J. 2022;40(2):120-126. Published online May 17, 2022
-
|
Purpose: The purpose of this study was to evaluate the treatment outcomes and toxicity profile of patients with early glottic cancer who underwent hypofractionated radiation therapy (RT) with 3.5 Gy per fraction.
Materials and Methods: A retrospective review was performed of the medical records of 35 patients with early stage (T1-2N0M0) glottic cancer who underwent definitive RT. The dose fractionation scheme... |
-
-
|
- Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study
- Budhi Singh Yadav
, Shipra Gupta , Divya Dahiya , Ankita Gupta , Arun Singh Oinam
-
Radiat Oncol J. 2022;40(2):127-140. Published online June 20, 2022
-
|
Purpose: To assess the feasibility of accelerated hypofractionated radiotherapy with simultaneous integrated boost (SIB) in patients with breast cancer.
Materials and Methods: A total of 27 patients after breast-conserving surgery were included in this study. Patients were planned on a four-dimensional computerized tomogram, and contouring was done using RTOG guidelines. The dose was 34 Gy/10#/2 week to the breast and 40... |
-
-
|
|
|
- Case Report
- Craniospinal irradiation for respiratory failure secondary to central nervous system Erdheim-Chester disease
- Rahul N. Prasad
, Peter J. Kobalka , Haley K. Perlow , Daniel M. Prevedello , Dukagjin M. Blakaj , Raju R. Raval , Joshua D. Palmer
-
Radiat Oncol J. 2022;40(2):162-168. Published online May 20, 2022
-
|
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis typically featuring lower extremity osteosclerosis (96%) from Langerin-negative histiocytes with fibrosis. Central nervous system (CNS)-only disease is extremely rare, and particularly difficult to diagnose and manage. Neurologic complaints may be refractory to systemic therapy (ST), and the role of radiation therapy (RT) is undefined. We present a patient with ECD of... |
-
-
|
|
|
|